Institutional Ownership
Alnylam Pharmaceuticals Inc
CUSIP 02043QAB3NOTE 1.000% 9/1ALNYQ1 2026
13D / 13G Filings
0
Schedule 13D/13G on record
Beneficial Filers
0
Distinct reporting persons
Largest Stake
—
Max % of class reported
Institutional Holders
9
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
Schedule 13D (activist) & 13G (passive) 5%+ ownership filings
No 13D/13G filings on record yet
Schedule 13D/13G beneficial-ownership filings from 2020–present are ingested from SEC EDGAR. Coverage expands as the backfill and daily crawler run.
Top Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Boussard & Gavaudan Investment Management LLP | 32.0K | $40.81M |
| 2 | Bnp Paribas Asset Management Holding S.A. | 9.75M | $12.56M |
| 3 | Ssi Investment Management LLC | 4.10M | $5.25M |
| 4 | Loomis Sayles & Co L P | 4.9K | $1.61M |
| 5 | Sei Investments Co | 251.0K | $321.7K |
| 6 | Bank Of New York Mellon Corp | 215.0K | $276.7K |
| 7 | Oppenheimer Asset Management Inc. | 81.0K | $103.8K |
| 8 | Stephens Inc /Ar/ | 24.0K | $30.8K |
| 9 | Mml Investors Services, LLC | 10.0K | $12.8K |